BI Asset Management Fondsmaeglerselskab A S Invests $2.17 Million in Insmed Incorporated (NASDAQ:INSM)

BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 31,390 shares of the biopharmaceutical company's stock, valued at approximately $2,167,000.

Several other large investors have also made changes to their positions in INSM. Sanctuary Advisors LLC purchased a new stake in Insmed during the third quarter worth $248,000. Tidal Investments LLC raised its position in Insmed by 447.0% during the third quarter. Tidal Investments LLC now owns 24,102 shares of the biopharmaceutical company's stock worth $1,759,000 after acquiring an additional 19,696 shares during the period. Principal Financial Group Inc. raised its position in Insmed by 12.9% during the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock worth $136,648,000 after acquiring an additional 214,130 shares during the period. Everence Capital Management Inc. acquired a new position in Insmed during the fourth quarter worth $352,000. Finally, Harbor Capital Advisors Inc. raised its position in Insmed by 237.1% during the fourth quarter. Harbor Capital Advisors Inc. now owns 59,600 shares of the biopharmaceutical company's stock worth $4,115,000 after acquiring an additional 41,918 shares during the period.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on INSM shares. Wells Fargo & Company upped their price objective on shares of Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 19th. Guggenheim restated a "buy" rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. JPMorgan Chase & Co. upped their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Truist Financial upped their price objective on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insmed Trading Up 1.1 %

Insmed stock traded up $0.73 during midday trading on Friday, hitting $69.69. 13,610,728 shares of the stock were exchanged, compared to its average volume of 2,306,722. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The stock has a market capitalization of $12.67 billion, a price-to-earnings ratio of -12.47 and a beta of 1.07. The stock's 50-day simple moving average is $74.38 and its 200 day simple moving average is $73.57. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. On average, equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current year.

Insider Activity

In related news, insider Martina M.D. Flammer sold 33,055 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the transaction, the insider now owns 138,053 shares of the company's stock, valued at $11,168,487.70. This represents a 19.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $70.16, for a total value of $479,192.80. Following the completion of the transaction, the chief executive officer now directly owns 233,924 shares in the company, valued at $16,412,107.84. This trade represents a 2.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 471,797 shares of company stock worth $37,621,239. Corporate insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.